Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ligand Pharmaceuticals has reported that its Captisol-enabled, propylene glycol-free (PG-free) melphalan drug met all the endpoints in patients with multiple myeloma.
Subscribe to our email newsletter
The Phase II study included comparison of the safety, tolerability and pharmacokinetic profiles of PG-free melphalan intravenous formulation to the standard multiple myeloma treatment.
The Captisol-enabled drug is said to provide longer administration durations and slower infusion rates, enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.
The trial was conducted in partnership with The University of Kansas Cancer Center was partially funded by the Kansas Bioscience Authority.